Congenital prothrombin defects: they are not only associated with bleeding but also with thrombosis: a new classification is needed

Antonio Girolami, Silvia Ferrari, Elisabetta Cosi, Bruno Girolami and Anna Maria Lombardi

Department of Medicine, University of Padua Medical School, Padua, Italy; Division of Medicine, Padua City Hospital, Padua, Italy

ABSTRACT

Objective: Congenital prothrombin deficiency is one of the rarest clotting disorders. It is commonly subdivided in Type I defects or cases of ‘true’ prothrombin deficiency characterized by a concomitant decrease in FIll activity and antigen and in Type II or dysprothrombinemias, in which FIll activity is low but FIll antigen is normal or near normal. A bleeding tendency, often a severe one, is the hallmark of the two-defects even though the bleeding is usually less severe in the Type 2 defects or dysprothrombinemias.

Patients and Methods: An extensive search of published cases of prothrombin deficiency was carried out in Pubmed and Scopus. The search started in 2012, after the publication of the first family with dysprothrombinemia and venous thrombosis. A few additional families were found.

Results: Recent studies have demonstrated that the Type 2 defects are heterogeneous. Several heterozygous mutations involving the Arg596 residue of exon 14 have been demonstrated not to be associated with a bleeding tendency but, surprisingly, with venous thromboses. Mutations in close areas of prothrombin have failed to show the same pattern.

Conclusions: These observations have required a reclassification of prothrombin defects. To the Type I and Type II defects, a Type III has to be added characterized by the absence of bleeding and the presence of venous thrombosis. It is not clear yet if this special variant of Type II defect is limited to the Arg596 mutations or if other residues may be involved.

KEYWORDS

Prothrombin deficiency; dysprothrombinemia; thrombosis; bleeding

Introduction

Prothrombin deficiency is one of the rarest coagulation disorders with a prevalence of about 1:1,500,000 [1–3]. The defect is usually classified in Type I in which there is a concomitant decrease of prothrombin activity and antigen and in Type II in which prothrombin activity is low, whereas antigen is normal or near normal. The first type is also known as ‘True’ deficiency or hypoprothrombinemia, whereas the latter is known as dysprothrombinemia. Association of hypoprothrombinemia with dysprothrombinemia (hypo-dysforms) has also been described. The same is true for the combination between two dysprothrombinemias (dys-dysforms) [1–3].

Altogether about 150 cases due to several mutations have been described so far. The defect has been described all over the world but it seems relatively more frequent in Latin countries and especially in Puerto Rico [1,4,5]. In this small island, isolation has allowed the diffusion of the autosomal recessive defect. It is estimated that, in that island, it may represent the third most frequent clotting defect after the hemophilia and von Willebrand Disease [4]. Prothrombin deficiency has been associated with a bleeding tendency, often a severe one. Complete absence of prothrombin is maintained to be incompatible with life [1–3].

Even homozygous with severe bleeding have prothrombin levels around 1% of normal. Usually compound heterozygotes between two Type 1 defects with hypoprothrombinemia have levels between 1 and 5% of normal and are always symptomatic. Compound heterozygotes between a Type 1 and a Type 2 defect have usually activity of 5–10% of normal but antigen may be 50–60% of normal [1–3,5]. They also may present an important bleeding tendency. Heterozygotes who have prothrombin activity around 40–55% of normal do not show usually spontaneous bleeding but they may bleed in case of surgery, deliveries or tooth extractions [1–3].

Till a few years ago no thrombosis has ever been described in patients with prothrombin deficiency and the condition was always considered a bleeding disorder, often a severe one. This assumption was demonstrated wrong in 2012 when a family with dysprothrombinemia with venous thrombosis was reported in Japan [6]. A few similar families were reported during the following years in Serbia, India, Italy [7–10]. All these patients had a mutation of amino acid Arg596. It was substituted by a leucine, a glutamine and a tryptophan. Another important feature was the absence of bleeding and the fact that the patients were all heterozygotes [6–10].
These new findings have clearly demonstrated that a new classification of prothrombin defects was needed.

**Updated classification**

Today we can classify prothrombin defects in three groups, namely: (1) true prothrombin deficiency (2) dysprothrombinemias with variable bleeding tendency and (3) dysprothrombinemia without bleeding but with thrombosis.

**True prothrombin deficiency**

The condition is characterized by a concomitant decrease of FII activity and FII antigen. Usually lower than 5% of normal. The condition is always associated with an important bleeding tendency. Even heterozygotes with FII levels of about 40–50% of normal may sometimes present undue bleeding during delivery, surgical procedures or tooth extractions [1–3].

**Dysprothrombinemias with variable bleeding tendency**

Dysprothrombinemias are defects characterized by variably activity, usually around 5–10% of normal and normal or near normal FII antigen. Occasionally, FII activity may be lower than that.

The bleeding tendency is variable but surely, less severe than that of the cases of ‘true’ deficiency. In some cases bleedings may be mild.

**Dysprothrombinemias with thrombosis**

Our knowledge about the dysforms have changed during the last few years. Actually the first data about the existence of a severe procoagulant state associated with a mild bleeding tendency dated back to 2002 [11].

In that year Akhavan et al. reported an 11 years old girl from Iran who had only a mild-to-moderate bleeding tendency despite having prothrombin level of less than 1% but an antigen level of 61%. On the suspicion of a dysfunctional protein further studies showed that the underlying mutation was Arg67His substitution (chymotrypsinogen numbering that is equivalent to the Arg382His mutation). Furthermore, it was demonstrated a decreased activation of protein C, a decreased binding to thrombomodulin, a severe impairment of thrombin inhibition by heparin cofactor II and, finally, a decrease of prothrombin activation by the FXa–FVa complex. The complex defect caused by the Arg67His mutation was cautiously concluded to affect both the coagulant and the anticoagulant activities of thrombin.

It was thought that there was a balance between these two opposing forces [11]. This interesting observation remained silent for several years and the prothrombin defects were always considered to be responsible of a bleeding tendency. Several dysprothrombinemias were reported but no thrombosis event was ever mentioned [2,3,12–17].

Then, in 2012, a female patient from Japan who had dysprothrombinemia was reported; she had no bleeding but a venous thrombosis [6]. The proposita was 12 years old and had her first thrombosis at the age of 11. The patient was demonstrated to have a prothrombin abnormality due to an Arg596Leu mutation that possessed a gain of function. The gain of function consisted in an increased resistance toward antithrombin. Immediately, after this first report, other similar cases were reported involving always the AA Arg596 but substituted by Gin or Trp, instead of Leu as in the original case [8–10].

The main features of these dysprothrombinemias are gathered in Table 1. The most important common aspect presented by this group of patients, regardless of the country of origin, Japan, Serbia, Italy, was the occurrence of venous thrombosis at a young age (11–27 years). In addition, they were also all heterozygotes and had no bleeding tendency. At about the same time a patient from India was reported (prothrombin Amrita) with a dysprothrombinemia due also to an Arg596Gln mutation [7]. However, this case shows some differences from the previous group, despite the same mutation, since the venous thrombosis occurred at the age of 60. Furthermore, there was no family story [7].

Recently, Ding et al. [18] reported a family in which there are two patients with an Arg382His mutation and an important bleeding tendency, one of whom had a post-partum deep vein thrombosis (DVT) and pulmonary embolism (PE) (Table 2).

The interesting peculiarity of this new family is that the proposita and her sister are homozygous for the defect (FII activity 1%; FII antigen, normal). All the other previous patients were heterozygous. The proposita is a 30 years old Chinese who had a DVT and PE 28 days post-partum and was treated with low molecular weight heparins and fresh frozen plasma. It is doubtful that this patient may be similar to the previous cases because the patient had received during pregnancy, because of bleeding, 600 Units of a prothrombin complex concentrates (PCC) every week, beginning on the sixth week of gestation for an approximate total of 20,400 Units. This prolonged replacement therapy could have created on the long run a thrombophilic state with consequent thrombosis. The patient never had other thrombosis. Furthermore, her homozygous sister never had thrombosis.

The Arg382His mutation does not belong to the classic group which involves Arg596Leu or Gin or Trp mutations. Due to the different site of the mutation, the condition has to be considered a dysprothrombinemia with both bleeding and thrombosis secondary to
### Table 1. Cases of prothrombin abnormalities due to mutations of Arg596 that are associated with a gain of function towards antithrombin and that therefore cause a thrombophilic state.

| Authors, year          | Age, sex | FII act | FII ant | Bleeding | Venous thrombosis (age at first episode) | Associated Risk | Mutation | Genotype | Eponym                  | Comments                                      |
|------------------------|----------|---------|---------|----------|------------------------------------------|-----------------|----------|----------|-------------------------|-----------------------------------------------|
| Miyawaki et al. (2012) | 17, F    | 37.6    | 63.8    | No       | Yes (11 Years)                           | No              | Arg596Leu | Het.     | Prothrombin Yukuhashi   | Patient from Japan                           |
| Djordjevic et al. (2013) | Fam 1   | n.r.    | n.r.    | n.r.     | Yes (17 years)                           | No              | Arg596Leu | Het.     | Prothrombin Belgrade     | Six patients in two families                  |
|                        | Fam 2    | n.r.    | n.r.    | n.r.     | Yes (16 years)                           | No              | Arg596Leu | Het.     | Prothrombin Belgrade     |                                               |
| Sivasundar et al. (2013) | 60, M    | n.r.    | n.r.    | n.r.     | Yes (15 years)                           | No              | Arg596Gln | Het.     | Prothrombin Amrita       | No founds study                               |
| Kishimoto et al. (2016) | 23, F    | n.r.    | n.r.    | No       | Yes (38 years)                           | No              | Arg596Trp | Het.     | Prothrombin Padua        | Patient from Japan                           |
| Bulato et al. (2016)    | 47, M    | 54      | 80      | No       | Yes (27 years)                           | No              | Arg596Trp | Het.     | Prothrombin Padua        | Seven patients in two families                |

Note: Het. = Heterozygote; n.r. = not reported. (a) Data supplied in ‘Correspondence’. N. Engl Med 2012; 367:1069–1070. Only the families with the Arg596 mutations are included.

### Table 2. Main features of the prothrombin defect, a dysprothrombinemias due to mutations not involving the Arg596 amino acid but still associated with thrombosis.

| Authors, year          | Age, sex | FII act | FII ant | Bleeding | Venous thrombosis (age at first episode) | Associated risks | Mutation | Genotype | Eponym                  | Comments                                      |
|------------------------|----------|---------|---------|----------|------------------------------------------|-----------------|----------|----------|-------------------------|-----------------------------------------------|
| Ding et al. (2017)     | 30, F    | 1       | 82.9    | Yes, severe | 30 | Pregnancy: Replacement therapy with PCC during most of the pregnancy | Arg382His     | Hom      | n.r.     | A sister similarly affected but without thrombosis |                                              |
intensive replacement therapy even though a contributory
effect of other factors cannot be excluded [18].
Thrombotic events, both arterial and venous, have
been described in several coagulation factors
deficiencies after or during replacement therapy [19–
23].

Discussion

An updated classification of prothrombin defects is the
following: Type 1 or cases of ‘true’ prothrombin
deficiency; Type II or cases with dysprothrombinemia
and a variable bleeding tendency, sometimes only mild
and Type III cases of dysprothrombinemia with
no bleeding but instead a prothrombotic state.

The observation that a clotting factor may be
associated both with bleeding and thrombosis,
depending on the site of the mutation has important
implications. It will be of paramount importance to
know the precise area of the protein which is critical
for this shift in behavior. Several dysprothrombinemias
with mutations in sites of the protein upstream on
downstream of the Arg596 site have been described
but no association with thrombosis has ever been
reported (Table 3). These dysprothrombinemias are
prothrombin Salakta (Gln509Ala), prothrombin Greenville
(Arg517Gln), prothrombin Perija (Gly548Ala),
prothrombin Scranton (Lys599Thr) and others show
mutation close to the Arg596 amino acid but appar-
etly no venous thrombosis has ever been reported
[12–17,24–26]. As far as we can tell the critical area
seems to reside around Arg596, site of the mutation
associated with a demonstrated occurrence of venous thrombosis.

These observations have further complicated our
appraisal of the clotting mechanism. It is noteworthy
to indicate that all patients with mutations in this
area but one, prothrombin (Leiden) [24] are Type 2
defects suggesting a role of the FII antigen in the
potential occurrence of thrombosis. This may explain
why no thrombotic event has ever been described in
patients with true prothrombin deficiency (Type I
defect) [27].

The new studies on prothrombin have modified our
understanding of prothrombin defects. The exclusively
bleeding tendency remains valid only for patients with
‘true’ deficiency [27]. Furthermore, the fate of the dys-
prothrombinemias results drastically changed. The dys-
prothrombinemias should be divided in a group with
only a mild bleeding tendency, tendency (Scranton,
Perija, etc.) and a group associated with venous throm-

Table 3. Main features of prothrombin defects close to the Arg596 amino acid.

| Eponym | Mutation | Genotype | Bleeding | Thrombosis | Type of defect | Amino acid |
|--------|----------|----------|----------|------------|---------------|------------|
| Salakta | Gln509Ala | Het      | No       | No         | II            | Arg596     |
| Greenville | Gln548Ala | Het      | Mild     | No         | II            | Arg596     |
| Perija | Gln548Ala | Hom      | No       | No         | II            | Arg596     |
| Scranton | Lys599Thr | Het      | Severe   | No         | II            | Arg596     |
| Yukuhashi | 599Stop+Arg596Stop | Het | Severe | No | II | Arg596 |

Note: No thrombotic event has been reported in any of these patients who are mainly affected by dysprothrombinemias or Type II defects. Only a defect due to a compound heterozygosis between Arg596Stop and a splicing defect is a Type I defect. Amino acid numbering includes the 43 residues of the pre-pro-sequence. References to the authors of the present paper.
for the occurrence of thrombosis. The extension of that area is unknown. Unfortunately, we do not know if patients with dysprothrombinemias due to mutations in areas close to the Arg596 amino acid had thrombotic events after the publication of the original reports.

The ‘thrombotic’ area probably involves only a few AA and it remains for future research to establish where the breaking points exist, if any. In fact, dysprothrombinemias both downstream and upstream of the Arg596 have been reported with no apparent association with thrombosis.

These developments on prothrombin are in agreement with recent studies involving FIX. A mutation (Arg338Lys) in exon 14 of FIX (FIX Padua) has been associated with a thrombophilic state due to highly increased FIX activity [28]. Here, again a factor which is involved in a severe bleeding condition, hemophilia B, may turn to be thrombophilic. The fact that some studies have demonstrated the rarity of this FIX mutation does not diminish the importance of the finding [29,30] as shown by the attempts to utilize this mutation to prepare high potency concentrates [31,32].

Reviews on prothrombin defects have to be rewritten since even the most recent ones had no opportunity to deal with these new developments [2,3].

Today, only Factor X defects remain thrombosis free [27]. FII and FIX defects could be defined as thrombo-hemorrhagic conditions or, better, as hemorrhagic-thrombotic disorders.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This study was supported in part by the ‘Associazione Emofilia ed alte Coagulopatie delle Tre Venezie’.

References

[1] Girolami A, Scarano L, Saggiorato G, et al. Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis. 1998;9:557–569.
[2] Lancellotti S, De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost. 2009;35:367–381.
[3] Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency: an update. Semin Thromb Hemost. 2013;39:596–606.
[4] Lefkowitz JB, Wellar A, Nuss R, et al. A common mutation, Arg457→Gln, links prothrombin deficiencies in the Puerto Rican population. J Thromb Haemost. 2003;1:2381–2388.
[5] Girolami A, Scandellari R, Scapin M, et al. Congenital bleeding disorders of the vitamin K-dependent clotting factors. Vitam Horm. 2008;78:281–374.
[6] Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med. 2012;366:2390–2396.
[7] Sivasundar S, Oommen AT, Prakash O, et al. Molecular defect of ‘Prothrombin Amrita’: substitution of arginine by glutamine (Arg553 to Gln) near the Na(+) binding loop of prothrombin. Blood Cells Mol Dis. 2013;50:182–183.
[8] Djordjevic V, Kovac M, Miljic P, et al. A novel prothrombin mutation in two families with prominent thrombophilia – the first cases of antithrombin resistance in a Caucasian population. J Thromb Haemost. 2013;11:1936–1939.
[9] Kishimoto M, Suzuki N, Murata M, et al. The first case of antithrombin-resistant prothrombin Belgrade mutation in Japanese. Ann Hematol. 2016;95:541–542.
[10] Bulato C, Radu CM, Campello E, et al. New prothrombin mutation (Arg596Trp, prothrombin Padua 2) associated with venous thrombembolism significance. Arterioscler Thromb Vasc Biol. 2016;36:1022–1029.
[11] Akhavan S, De Cristofaro R, Peyvandi F, et al. Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood. 2002;100:1347–1353.
[12] Henrikson RA, Dunham CK, Miller LD, et al. Prothrombin Greenville, Arg517→Gln, identified in an individual heterozygous for dysprothrombinemia. Blood. 1998;91:2026–2031.
[13] Henrikson RA, Owen WG, Nesheim ME, et al. Identification of a congenital dysthrombin, thrombin quick. J Clin Invest. 1980;66:934–940.
[14] Miyata T, Aruya R, Umeyama H, et al. Prothrombin Salakta: substitution of glutamic acid 466 by alanina residues the fibrinogen clotting activity and the esterase activity. Biochem. 1992;31:7457–7462.
[15] Sun WY, Smirnow D, Jenkins ML, et al. Prothrombin Scrantons: substitution of an amino acid residue involved in the binding of Na+ (LYS-556 to THR) leads to dysprothrombinemia. Thromb Haemost. 2001;85:651–654.
[16] Sekine O, Sugo T, Ebisawa K, et al. Substitution of Gly-548 to Ala in the substrate binding pocket of prothrombin Perijia leads to the loss of thrombin proteolytic activity. Thromb Haemost. 2002;87:282–287.
[17] Stanchev H, Philips M, Villoutreix BO, et al. Prothrombin deficiency caused by compound heterozygosity for two novel mutations in the prothrombin gene associated with a bleeding tendency. Thromb Haemost. 2006;95:195–198.
[18] Ding Q, Yang L, Zhao X, et al. Paradoxical bleeding and thrombotic episodes of dysprothrombinemia due to a homozygous Arg382His mutation. Thromb Haemost. 2017;117:479–490.
[19] Lusher JH. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol. 1991;28:3–5.
[20] Girolami A, Tezza F, Scandellari R, et al. Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. critical review of the literature. J Thromb Thrombolysis. 2010;30:172–178.
[21] Girolami A, Ruzzon E, Fabris F, et al. Myocardial infarction and other arterial occlusions in hemophilia a patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol. 2006;116:120–125.
[22] Girolami A, Cosi E, Tasinato V, et al. Pulmonary embolism in congenital bleeding disorders: intriguing discrepancies among different clotting factors deficiencies. Blood Coagul Fibrinolysis. 2016;27:517–525.
[23] Girolami A, Bertozzi I, Rigoni I, et al. Congenital FVII deficiency and thrombotic events after replacement therapy. J Thromb Thrombolysis. 2011;32:362–367.

[24] Poort SR, Njo KT, Vos HL, et al. Two novel mutations in the prothrombin gene cause severe bleeding in a compound heterozygous patient. Blood Coagul Fibrinolysis. 1998;9:761–764.

[25] Akhavan S, Mannucci PM, Lak M, et al. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost. 2000;84:989–997.

[26] O’Marcaigh AS, Nichols WL, Hassinger NL, et al. Genetic analysis and functional characterization of prothrombins Corpus Christi (Arg382-Cys), Dhahran (Arg271-His), and hypoprothrombinemia. Blood. 1996;88:2611–2618.

[27] Girolami A, Candeo N, Vettore S, et al. The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency. J Thromb Thrombolysis. 2010;29:299–302.

[28] Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361:1671–1675.

[29] De Moraes Mazetto B, Orsi FL, Siqueira LH, et al. Prevalence of factor IX-R338L (factor IX Padua) in a cohort of patients with venous thromboembolism and mild elevation of factor IX levels. Thromb Res. 2010;126:603.

[30] Koenderman JS, Bertina RM, Reitsma PH, et al. Factor IX-R338L (factor IX Padua) screening in a Dutch population of sibpairs with early onset venous thromboembolism. Thromb Res. 2011;128:603.

[31] Monahan PE, Sun J, Gui T, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther. 2015;26:69–81.

[32] Cantore A, Nair N, Della Valle P, et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood. 2012;120(23):4517–4520.